Trials / Conditions / Refractory B-Cell Lymphoma

Refractory B-Cell Lymphoma

8 registered clinical trials studyying Refractory B-Cell Lymphoma — 3 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	Treatment of Relapsed or Refractory B-cell Lymphoma With Chimeric Antigen Receptor (CAR) T-cell Therapy Produc NCT06378190	Instituto de Investigación Biomédica de Salamanca	Phase 1 / Phase 2
Recruiting	Chidamide Combined With Linperlisibon for the Treatment of Refractory/Relapsed Follicular Lymphoma NCT06158386	The First Affiliated Hospital of Xiamen University	Phase 2
Unknown	PSB202 in Patients With Previously Treated-, Relapsed-, Indolent B-Cell Malignancies NCT05003141	Qilu Puget Sound Biotherapeutics (dba Sound Biologics)	Phase 1
Recruiting	Study of CAR-T Therapy in Older Patients NCT04300998	Memorial Sloan Kettering Cancer Center	—
Unknown	Study of Anti-CD19 CAR NK Cells in Relapsed and Refractory B Cell Lymphoma NCT03690310	Allife Medical Science and Technology Co., Ltd.	EARLY_Phase 1
Unknown	Study of Anti-CD22 CAR NK Cells in Relapsed and Refractory B Cell Lymphoma NCT03692767	Allife Medical Science and Technology Co., Ltd.	EARLY_Phase 1
Unknown	Study of Anti-CD19 iCAR NK Cells in Relapsed and Refractory B Cell Lymphoma NCT03824951	Allife Medical Science and Technology Co., Ltd.	EARLY_Phase 1
Unknown	Study of Anti-CD19/CD22 CAR NK Cells in Relapsed and Refractory B Cell Lymphoma NCT03824964	Allife Medical Science and Technology Co., Ltd.	EARLY_Phase 1